TCBPY (TC BioPharm (Holdings)) ROCE %: -387.50% (As of Dec. 2024)


What is TC BioPharm (Holdings) ROCE %?

TC BioPharm (Holdings) TCBPY ROCE % is -387.50% as of Dec. 2024.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TC BioPharm (Holdings)'s annualized ROCE % for the quarter that ended in Dec. 2024 was -387.50%.

TC BioPharm (Holdings)  (OTCPK:TCBPY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TC BioPharm (Holdings) ROCE % Related Terms

TC BioPharm (Holdings) ROCE % Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) ROCE % Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial -138.08 0.00 0.00 -221.99 -306.11

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -117.42 -542.60 43.36 -293.01 -387.50

TC BioPharm (Holdings) ROCE % Calculation

TC BioPharm (Holdings)'s annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-16.19/( ( (11.306 - 6.014) + (10.53 - 5.244) )/ 2 )
=-16.19/( (5.292+5.286)/ 2 )
=-16.19/5.289
=-306.11 %

TC BioPharm (Holdings)'s ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-18.482/( ( (8.742 - 4.489) + (10.53 - 5.244) )/ 2 )
=-18.482/( ( 4.253 + 5.286 )/ 2 )
=-18.482/4.7695
=-387.50 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -387.50% mean?
TC BioPharm (Holdings) (TCBPY) has a ROCE % of -387.50% as of Dec. 2024.
Is TC BioPharm (Holdings)'s ROCE % too high?
TC BioPharm (Holdings)'s current ROCE % is -387.50%.
How does TC BioPharm (Holdings)'s ROCE % compare to SIGY and CNBX?
TC BioPharm (Holdings)'s ROCE % of -387.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. TC BioPharm (Holdings)'s current ROCE % is -387.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current ROCE % of -387.50%. The current ROCE % is -387.50%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current ROCE % is -387.50% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.